Maze Therapeutics Appoints Jason Coloma as Chief Executive Officer and Expands Leadership Team

Matt Krause Appointed as Senior Vice President of Human Resources

SAN FRANCISCO–(BUSINESS WIRE)–Maze
Therapeutics, a company focused on translating genetic insights into
new medicines, today announced that Jason Coloma, Ph.D., Maze’s current
chief operating officer, has been appointed as chief executive officer.
He succeeds interim CEO, Charles Homcy, M.D., who will assume the role
of chairman of the company’s board of directors. In addition, Maze
announced the appointment of Matt Krause, a nearly 25-year human
resources leader, as senior vice president of human resources.

“Beginning with the initial idea for the company, through our launch to
today, Jason has been instrumental in the success of Maze. We are
thrilled that he will continue to lead the company as CEO,” said Dr.
Homcy. “As we look ahead, Maze is focused on leveraging our expertise in
human genetics and functional genomics to create important new medicines
for a number of diseases. To be successful, we will need to continue
hiring the best minds in the industry, and we look forward to leveraging
Matt’s experience to build a unique and diverse company. Maze is built
on world-class science, and as chairman of the board of directors, I’m
excited to continue to participate in its evolution.”

“Since launching earlier this year, the Maze team has made tremendous
progress advancing our approach of translating genetic insights into new
therapeutics,” said Dr. Coloma. “I am very excited about the potential
of Maze to make a difference in the future of human health and medicine,
which contributed to my decision to leave Third Rock and join Maze as
full-time CEO. We are thankful to Charles and all that he has done to
bring Maze from an idea to a reality, and look forward to continuing our
work together with him leading our board of directors.”

About Dr. Jason Coloma

Prior to joining Maze, Dr. Coloma was a venture partner at Third Rock
Ventures, where he focused on new company formation. He has also held
interim chief business officer roles with Third Rock portfolio companies
insitro and Celsius. Prior to joining Third Rock, Dr. Coloma was the
senior vice president and chief business officer at Corvus
Pharmaceuticals. Previously, he held a number of roles at Roche,
including vice president & global therapeutic area head of oncology and
cancer immunotherapy partnering. Before joining Roche, Dr. Coloma was a
consultant in the life sciences practice at L.E.K. Consulting. He also
worked in finance at Amgen and in research at the University of
California, San Francisco and Cytokinetics. Dr. Coloma holds a Ph.D. and
M.P.H. at the University of California, Berkeley, an MBA from the Tuck
School of Business at Dartmouth and a B.S. in biology from the
University of San Francisco.

About Matt Krause

Mr. Krause has spent his nearly 25-year career in human resources
helping companies build experienced teams. He joins Maze from Global
Blood Therapeutics where he served as vice president of human resources
and helped build out the team starting from company formation through
clinical development. Prior to Global Blood, Mr. Krause held a number of
senior director and representative roles in human resources, including
at Audience, Inc., Amyris Biotechnology, CV Therapeutics, CopperCom,
Gilead Sciences, Bio-Rad Laboratories and DNA Plant Technology. Mr.
Krause holds an M.S. in industrial relations from the University of
Oregon and received a B.S. in business administration and finance from
California State University, Long Beach.

About Maze Therapeutics

Maze Therapeutics is translating novel genetic insights into lifesaving
medicines, through an approach that integrates human genetics and
functional genomics. Advances in these areas, coupled with deep
biological insights and advanced data science tools, have enabled Maze
to understand the ways modifier genes can confer protection. Maze will
create therapies that mimic protective modifiers. The company was
launched in 2019 by Third Rock Ventures, with funding from ARCH Venture
Partners, GV, Foresite Capital, Casdin Capital, Alexandria Venture
Investments and other undisclosed investors. For more information please
visit mazetx.com.

Contacts

Media Contact
Katie Engleman, 1AB
[email protected]